Drug Trial Radar · NCT07850453
Vortosiran for VTE Prevention
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Jul 2027
Study completion May 2028
Sponsor
- Lead sponsor
- Ribocure Pharmaceuticals ABIndustry
- Sponsor type
- Industry
- Collaborators
- Fortrea
- First posted
- Sep 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Blood clots remain a serious cause of illness and death. Long-term treatment and prevention of these clots with blood thinners is often limited by bleeding risk, drug interactions, and daily dosing, leading many patients to stop treatment early. Both cancer and chemotherapy further increase the risk of clot formation. Vortosiran is an injectable therapy that lowers Factor XI (one of the body's natural clotting helpers) production in the liver, leading to a strong and long-lasting reduction in blood clotting activity with less risk of bleeding compared to current available treatments. Studies conducted so far have shown that vortosiran is safe and shows a dose-dependent Factor XI suppression (that is, a higher dose results in a higher level of suppression) that lasts for several months, supporting testing using a limited number of injections in patients who are at higher risk of blod clot formation. This study aims to study how safe and effective vortosiran is in patients who have had blood clots in the past and in cancer patients who are at high risk of developing blood clots.
Conditions
- Venous Thromboembolism (VTE)
- Cancer
- Pulmonary Embolism (Diagnosis)
Interventions
VortosiranDrug
Vortosiran, active drug.
PlaceboDrug
Placebo that is identical in appearance of active IMP.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary objectiveTime frame: At Week 8
- Primary endpointTime frame: Baseline to Week 8.
Locations
30 sites in 4 countries. Site status is shown where the registry gives one.
Multiprofile Hospital For Active Treatment - Pazardzhik AD
Pazardzhik, Bulgaria
Specialized Hospital for Active Treatment in Cardiology - Medica Cor EAD
Rousse, Bulgaria
Acibadem City Clinic Tokuda University Hospital EAD
Sofia, Bulgaria
Multiprofile Hospital for Active Treatment "National Cardiology Hospital" EAD
Sofia, Bulgaria
Multiprofile Hospital for Active Treatment "National Cardiology Hospital" EAD
Sofia, Bulgaria
University Hospital for Active Treatment and Emergency Medicine N.I. Pirogov EAD
Sofia, Bulgaria
University Multiprofile Hospital for Active Treatment "Alexandrovska"
Sofia, Bulgaria
Multiprofile District Hospital for Active Treatment "Dr. Stefan Cherkezov" AD
Veliko Tarnovo, Bulgaria
Centre Oncologie Radiotherapie (CORT 37)
Chambray-lès-Tours, France
Louis-Mourier (AP-HP)
Colombes, France
CHU de Grenoble
Grenoble, France
Hôpital Européen Georges Pompidou (HEGP)
Paris, France
Cardiology Office Individual Specialist Medical Practice Elżbieta Dułak
Gdynia, Poland
Oddział Kardiologii SPS Szpital Zachodni im św Jana Pawła iI
Grodzisk Mazowiecki, Poland
Uniwersytet Jagiellonski Collegium Medicum
Krakow, Poland
"Department of Cardiology European Health Center Otwock"
Otwock, Poland
University Clinical Research Support Center of Medical University in Poznan
Poznan, Poland
Clinical Oncology Department, Mazowiecki Szpital Wojewódzki
Siedlce, Poland
Aidport Sp. z o.o.
Skorzewo, Poland
Zachodniopomorskie Centrum Onkologii
Szczecin, Poland
Centrum Medyczne LUX MED sp zoo ul 1 Sierpnia 8, 02-143 Warszawa
Warsaw, Poland
Klinika Sienna Sp. z o.o.
Warsaw, Poland
Maria Skłodowska-Curie National Research Institute of Oncology
Warsaw, Poland
Gral Medical - Oncofort Pitesti
Piteşti, Romania
Satu Mare County Emergency Hospital
Satu Mare, Romania
Spitalul European Polisano - Constitutiei Sibiu
Sibiu, Romania
Sigmedical Services S.R.L.
Suceava, Romania
Centrul Medical Cardiomed
Târgu Mureş, Romania
Spitalul Clinic Judeţean Mureş
Târgu Mureş, Romania
Institutului de Boli Cardiovasculare Timişoara
Timișoara, Romania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.